Pharma Focus Asia

Adaptation Of Targeted Nanocarriers To Changing Requirements In Antimalarial Drug Delivery

Authors: Joana Marques, Juan Jose Valle-Delgado, Patricia Urban, Elisabet Baro, Rafel Prohens, Alfredo Mayor, Pau Cistero, Michael Delves, Robert E. Sinden, FMedScie, Christian Grandfils, José L. de Paz, José A. García-Salcedo, Xavier Fernàndez-Busquets

Abstract:

The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.

Graphical Abstract

Preexisting antimalarial nanocarriers and targeting molecules (gray boxes) have been modified in their nanocapsule, targeting molecule and drug cargo to adapt them to new therapeutic strategies against malaria parasites

Key words

Glycosaminoglycans; Malaria; Nanomedicine; Plasmodium; Targeted drug delivery

Citation: Joana Marques, Juan Jose Valle-Delgado, Patricia Urban, Elisabet Baro, Rafel Prohens, Alfredo Mayor, Pau Cistero, Michael Delves, Robert E. Sinden, FMedScie, Christian Grandfils, José L. de Paz, José A. García-Salcedo, Xavier Fernàndez-Busquets Adaptation Of Targeted Nanocarriers To Changing Requirements In Antimalarial Drug Delivery http://dx.doi.org/10.1016/j.nano.2016.09.010

Received: 13 November 2015, Accepted: 25 September 2016, Available online: 5 October 2016

Copyright: © 2016 2016 Published by Elsevier Inc.

Acknowledgments

We are indebted to the Cytomics Unit of the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) for technical help, and to Dr. Joan Estelrich (Departament de Fisicoquímica, Facultat de Farmàcia, Universitat de Barcelona) for access to liposome assembly facilities.

Latest Issue
Get instant
access to our latest e-book
MFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Gibco Adherent Kidney Media PanelCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024